Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals
•Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits
•Women of childbearing potential must agree to use contraception for the entire study period

•Any dermatological conditions that could interfere with clinical evaluations
•Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
•Significant confounding conditions as assessed by study doctor
•Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study
•Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
•Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months
•Pregnancy or lactation